Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15648680 | 0.98 | — | — | |
| SCHEMBL30825510 | 0.74 | — | — | |
| SCHEMBL1795212 | 0.72 | MEN1 (0.43) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Hydrochloric Acid SCHEMBL26131782 | 0.71 | MEN1 (0.38) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL5431792 | 0.70 | MEN1 (0.41) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL16878106 | 0.70 | MEN1 (0.41) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Hydrochloric Acid SCHEMBL26964791 | 0.70 | HIF1A (0.33) | — | |
| Hydrochloric Acid SCHEMBL26123694 | 0.70 | HIF1A (0.33) | — | |
| Hydrochloric Acid SCHEMBL30548084 | 0.69 | MEN1 (0.31) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Hydrochloric Acid SCHEMBL30922532 | 0.69 | MEN1 (0.31) | MEN1KMT2AKDM4EGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250122222-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250019377-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-01-16 | — | — | US | disclosed |
| EP-4387967-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-26 | — | — | EP | disclosed |
| CN-118139855-A | 1, 4-Oxaazepane derivatives and their use | 北京加科思新药研发有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11939327-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-26 | — | — | US | disclosed |
| CN-112867715-B | 5-azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2024-03-05 | — | — | CN | disclosed |
| EP-3693360-B1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230278999-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-07 | — | — | US | disclosed |
| CN-112867715-A | 5-azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3693360-A1 | HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20200247801-A1 | HETEROCYLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-3237423-B1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | LILLY CO ELI (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3237423-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | Eli Lilly and Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20160375030-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-12-29 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | GAA 1240/4885MEN1 422/4885KMT2A 1903/4885 |
| US-20160375030-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | GAA 4301/4885MEN1 3266/4885KMT2A 3179/4885 |
| US-20250019377-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | CYP11B2, CYP21A2, CYP11B1 | GAA 774/4885MEN1 1708/4885KMT2A 2676/4885 |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | GAA 1328/4885MEN1 489/4885KMT2A 1892/4885 |
| US-20160176896-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | GAA 4301/4885MEN1 3266/4885KMT2A 3179/4885 |
| US-20230278999-A1 | HETEROCYCLIC COMPOUNDS | GRIN2C, GRIN1, GRIN2A | GAA 885/4885MEN1 4137/4885KMT2A 570/4885 |
| US-11939327-B2 | Heterocyclic compounds | GRIN2C, GRIN1, GRIN2A | GAA 898/4885MEN1 4140/4885KMT2A 579/4885 |
| US-20200247801-A1 | HETEROCYLIC COMPOUNDS | GRIN1, GRIN2A, GRIN2C | GAA 786/4885MEN1 4032/4885KMT2A 547/4885 |
| US-20250122222-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | GAA 1072/4885MEN1 212/4885KMT2A 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.